Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | CALM1 | P0DP23 | 3/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10026838 | 0.87 | TACR1 (0.42) | ALDH1A1CYP19A1CALM1CYP1A1CYP1B1 | |
| SCHEMBL14882621 | 0.86 | DAO (0.44) | ALDH1A1CYP19A1CALM1AKR1B1CA1 | |
| SCHEMBL13547916 | 0.86 | CYP4F2 (0.39) | ALDH1A1CYP19A1CALM1TSHRCA1 | |
| SCHEMBL9885348 | 0.82 | RXRA (0.44) | ALDH1A1CYP19A1CALM1 | |
| SCHEMBL10207847 | 0.82 | ALDH1A1 (0.48) | ALDH1A1CYP19A1CALM1AKR1B1CYP1A1 | |
| SCHEMBL20090425 | 0.81 | CYP19A1 (0.59) | CYP19A1CALM1AKR1B1PTGS2GABRA1 | |
| SCHEMBL10213407 | 0.81 | CYP19A1 (0.35) | ALDH1A1CYP19A1CALM1AKR1B1CA1 | |
| SCHEMBL10293222 | 0.80 | ALDH1A1 (0.46) | ALDH1A1CYP19A1CALM1AKR1B1CYP1A1 | |
| SCHEMBL21727714 | 0.79 | ALDH1A1 (0.44) | ALDH1A1CYP19A1CALM1AKR1B1CYP1A1 | |
| SCHEMBL73635 | 0.79 | TAAR1 (0.56) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374006-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230374006-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230047178-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | APRINOIA THERAPEUTICS INC. (CN) | 2023-02-16 | — | — | US | disclosed |
| US-20230042837-A1 | CYCLIC COMPOUNDS FOR TREATING CANCER | UNIVERSITY OF SOUTH FLORIDA | 2023-02-09 | — | — | US | disclosed |
| US-20230008571-A1 | CYCLIC COMPOUNDS FOR TREATING CARDIOVASCULAR DISORDERS AND WOUNDS | UNIVERSITY OF SOUTH FLORIDA | 2023-01-12 | — | — | US | disclosed |
| US-20210253569-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | APRINOIA THERAPEUTICS INC. (CN) | 2021-08-19 | — | — | US | disclosed |
| US-11078233-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20090137601-A1 | L-Phenylalanine Derivatives | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
| US-20080280899-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| US-20080200459-A1 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-21 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | METHYLGENE, INC. (CA) | 2007-07-05 | — | — | US | disclosed |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078233-B2 | Tripeptide epoxy ketone protease inhibitors | PREP, CTRL, ENPEP | ALDH1A1 1694/4885CYP19A1 390/4885CALM1 4369/4885 |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | CCR7, ACKR3, CCR2 | ALDH1A1 1954/4885CYP19A1 551/4885CALM1 4479/4885 |
| US-20230374006-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | MAPT, APP, SLCO1B3 | ALDH1A1 1918/4885CYP19A1 2074/4885CALM1 1301/4885 |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | ALDH1A1 4701/4885CYP19A1 4531/4885CALM1 1559/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | ALDH1A1 4701/4885CYP19A1 4531/4885CALM1 1559/4885 |
| US-20080280899-A1 | Inhibitors of Akt Activity | AKT1, AKT2, AKT3 | ALDH1A1 3486/4885CYP19A1 2558/4885CALM1 1573/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | ALDH1A1 3887/4885CYP19A1 543/4885CALM1 4257/4885 |
| US-20210253569-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | MAPT, APP, SLCO1B3 | ALDH1A1 1918/4885CYP19A1 2074/4885CALM1 1301/4885 |
| US-20230047178-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | MAPT, APP, SLCO1B3 | ALDH1A1 1918/4885CYP19A1 2074/4885CALM1 1301/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | ALDH1A1 148/4885CYP19A1 1043/4885CALM1 1278/4885 |
| US-20230008571-A1 | CYCLIC COMPOUNDS FOR TREATING CARDIOVASCULAR DISORDERS AND WOUNDS | TNNI3, EGFR, BDKRB2 | ALDH1A1 3967/4885CYP19A1 3040/4885CALM1 953/4885 |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | DNMT3B, DNMT1, DNMT3L | ALDH1A1 216/4885CYP19A1 1349/4885CALM1 3127/4885 |
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | HDAC5, HDAC4, HDAC3 | ALDH1A1 728/4885CYP19A1 805/4885CALM1 3566/4885 |
| US-20090137601-A1 | L-Phenylalanine Derivatives | ITGB5, ITGB1, ITGA2B | ALDH1A1 1156/4885CYP19A1 4808/4885CALM1 327/4885 |
| US-20230042837-A1 | CYCLIC COMPOUNDS FOR TREATING CANCER | EGFR, ERBB3, ERBB2 | ALDH1A1 4556/4885CYP19A1 4076/4885CALM1 2619/4885 |
| US-20080200459-A1 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | ALDH1A1 2247/4885CYP19A1 709/4885CALM1 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.